Ron Alfa, MD, Ph.D, Recursion Pharmaceuticals

Ron Alfa, MD, Ph.D

Dr. Alfa is Vice President, Discovery and Product at Recursion Pharmaceuticals (, an AI-enabled drug discovery company combining state-of-the-art machine learning with automated cell biology. At Recursion, he leads Product across the organization working closely with all teams to leverage computational tools & robotics to solve important drug discovery challenges. He received training in Neurosciences, Medicine, and Entrepreneurship at Stanford University and has made scientific contributions to the fields of Neurosciences, Metabolism, and Genetics. Prior to Recursion, Dr. Alfa worked closely with biotech start-ups at Stanford-affiliated accelerator, StartX.


11:35 AM - 11:50 AM

Deploying AI Tools to Accelerate Each Step in the Drug Discovery Pipeline

While we may still be a decade away from fully in silico drug discovery, AI has proven to have vast potential in this area.  Expanding and accelerating traditional approaches like phenotypic screening provide a feasible near-term solution to bringing substantial improvements to the efficiency of discovery and development efforts.  This session will describe technical strategies to accelerate discovery using AI, including an image-based phenotypic screening platform.  The use of deep learning models to build predictive tools for multiple stages in the drug discovery pipeline will also be discussed.

Download Latest Agenda